Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568627 · ClinicalTrials.gov registry record · Phase 3
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
A Phase 3 study of Venous Leg Ulcer (VLU), sponsored by MediWound.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
- 5
- Study locations
NCT06568627: Recruiting Phase 3 study of Venous Leg Ulcer (VLU), sponsored by MediWound.
NCT06568627 is a Phase 3 study of Venous Leg Ulcer (VLU) that is actively recruiting participants, run by MediWound. The registered enrollment target is 216 participants, roughly in line with the 202-participant average among 6 other Venous Leg Ulcer (VLU) trials with a reported enrollment target. The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06568627, a Phase 3 study of Venous Leg Ulcer (VLU), is actively recruiting participants, sponsored by MediWound.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).
Primary Outcome
counting events of complete debridement
Conditions Studied
Interventions
- DRUG EscharEx (EX-03)
- DRUG Placebo (Gel vehicle)
Study Locations (5)
California
- Limb Preservation Platform, Inc - Fresno
- Center for Clinical Research INC - San Francisco
Texas
- JPS Health Network/Acclaim Multispecialty Clinic - Fort Worth
- University of Texas Health Science Center at San Antonio - San Antonio
New York
- Northwell Health Comprehensive Wound Healing Center - Lake Success
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
What NCT06568627 shows while recruiting
NCT06568627 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 202-participant average among 6 other Venous Leg Ulcer (VLU) trials with a reported enrollment target.
The record links to 1 condition, with Venous Leg Ulcer (VLU) appearing as the primary indexed condition, and to 2 interventions - of which EscharEx (EX-03) is the first listed.
NCT06568627 lists 5 locations in 3 states (California, Texas, New York).
Frequently Asked Questions
What is clinical trial NCT06568627 about?
NCT06568627 is a clinical study titled "A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)". The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).
What is the current status of trial NCT06568627?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2025-06-01. Estimated completion is 2027-03.
What conditions does trial NCT06568627 study?
This clinical trial studies the following conditions: Venous Leg Ulcer (VLU).
What interventions are being tested in trial NCT06568627?
The interventions under investigation include: EscharEx (EX-03) (DRUG), Placebo (Gel vehicle) (DRUG).
Who is sponsoring clinical trial NCT06568627?
This trial is sponsored by MediWound, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568627 being conducted?
This trial has 5 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Leg Ulcer (VLU)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial to Evaluate Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic Venous Leg Ulcers
RECRUITING · Phase 4
-
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
RECRUITING · Phase 4
-
Evaluating the Durability of Closure for Venous Leg Ulcers
RECRUITING
-
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
RECRUITING · Phase 4
-
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers
RECRUITING · Phase 4
-
A Real World Data Collection OF Human Amniotic Membrane(s) ON Diabetic Foot Ulcers, Venous LEG Ulcers, Pressure Ulcers AND Post Operative Wounds
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI